U

University of Iowa Hospitals | Infectious Diseases Department

Research site

(Unclaimed)

Location

200 Hawkins Dr, Iowa City, Iowa, United States of America

Site insights

Top conditions

Top treatments

Armodafinil

Pembrolizumab

AS1413

ASP1002

ASP2074

Daclizumab

Rucaparib

Gemcitabine

Cytarabine

APL-2

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 25 total trials

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting

FIGO Stage III-IV

Newly Diagnosed

Drug: Placebo Oral Tablet

Drug: Nivolumab

A Study of ASP1002 in Adults for Treatment of Solid Tumors

The main aims of this study are:* To check the safety of ASP1002 in people with certain solid tumors.* To check if the people can tolerate ASP1002.*...

Enrolling

Advanced Solid Tumors

Drug: ASP1002

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used toget...

Active, not recruiting

Endometrial Carcinoma

Squamous Cell Carcinoma of the Head and Neck

Biological: Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)

Biological: Acasunlimab

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected...

Enrolling

Advanced Unresectable Solid Tumor

Metastatic Solid Tumor

Drug: Toripalimab

Drug: TAB004